This document is an investor presentation for Q1 FY27 (quarter ending June 2026) submitted to BSE Limited and the National Stock Exchange of India Limited pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q1 FY27 Financial Performance (₹ in Crores)

The company reported strong financial results for the quarter:

  • Revenue: ₹193.81 Crores, representing a 3.93% year-over-year (YoY) increase from Q1 FY26 revenue of ₹186.48 Crores.
  • EBITDA: ₹19.36 Crores, a significant 41.56% YoY increase from ₹13.68 Crores in Q1 FY26.
  • PBT (Profit Before Tax): ₹16.93 Crores, showing robust growth of 54.55% YoY from ₹10.95 Crores.
  • PAT (Profit After Tax): ₹11.42 Crores, up 37.63% YoY from ₹8.30 Crores.
  • EPS: ₹1.14, corresponding to the 37.63% PAT growth.

Quarter-over-quarter (QoQ) performance showed a revenue decline of 4.11% from Q4 FY26's ₹202.12 Crores, but profitability metrics improved significantly with EBITDA growing 3.95% QoQ from ₹18.63 Crores.

Operational Performance

Key operational metrics demonstrated substantial improvement:

  • Production Volume: 491 Metric Tons (MT), a 19.46% increase YoY.
  • ROCE (Return on Capital Employed): 19.18%, an improvement of 326 basis points.

Balance Sheet & Shareholder Returns

The presentation highlights the company's strong financial position, mentioning a debt-free balance sheet and a consistent dividend record. A dividend for FY26 was proposed.

Business Overview & Market Position

Anuh Pharma is an API manufacturer established in 1989. Key business highlights include:

  • It is one of the largest manufacturers of Macrolides and Anti-TB products in India.
  • The business portfolio includes Anti-bacterials, Anti-malarial, Antihypertension, and Corticosteroids.
  • It has 360 marketing partners/customers in over 72 countries.
  • ~46% of FY26 revenue came from exports.
  • The company holds a leading market position in several APIs including Erythromycin salts, Pyrazinamide, Sulfadoxine, Ambroxol HCL, Gliclazide, Clobetasol Propionate, and Betamethasone Dipropionate.

Regulatory Approvals & Infrastructure

The company's competitive advantage is supported by significant regulatory approvals:

  • Manufacturing facilities at Tarapur are approved by USFDA, EU GMP (AEMPS Spain), and are WHO pre-qualified.
  • The Tarapur facility spans 11,400 sq. meters with 9 API blocks and 2 intermediate blocks.
  • Total production capacity is 2,400 MTPA.
  • The facility features a Zero Liquid Discharge (ZLD) effluent control system.
  • A dedicated R&D facility is located at Mahape, Navi Mumbai (10,000 sq. ft., DSIR-approved).

Management Commentary

A message from Joint Managing Directors Ritesh Shah and Vivek Shah stated that profit growth outpaced revenue due to a strategic shift towards higher-value products in regulated markets. The growth was driven by a richer product mix, disciplined cost control, and better throughput from existing assets. They noted that with USFDA and EU GMP clearances secured, the regulated-market pipeline is the primary growth engine.

Future Outlook

The company's growth strategy targets a 15-20% per annum steady growth rate through:

  • Volume expansion across API lines and high-value regulated market growth.
  • Process innovation and cost optimization.
  • Strategic market diversification focusing on exports.
  • Continued investments in compliance, operational efficiency, and capacity enhancement.

Corporate Social Responsibility (CSR)

The presentation lists CSR initiatives undertaken with various foundations, including building a toilet block for a school, educational projects for underprivileged children, promoting sports for specially challenged children, providing recycled footwear, and supporting menstrual hygiene initiatives.